• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与人β-微管蛋白亚型的一个子集发生特异性反应的人血清。

Human serum reacting specifically with a subset of beta-tubulin isoforms.

作者信息

Edde B, Vandaele S, Darmon M, Soubiran P

机构信息

Laboratoire de Biochimie Cellulaire, Collège de France, Paris.

出版信息

Biol Cell. 1988;62(2):157-163.

PMID:3134072
Abstract

The serum of a patient suffering from myeloma was found to decorate microtubules and mitotic spindles of cultured cells. Immunoblots performed after one- and two-dimensional electrophoresis showed a reaction with a certain subset of beta-tubulin isoforms, but not with beta'- and alpha-tubulins. The tubulin subset contained both ubiquitous (beta-3) and neurospecific (beta-4,5,6) isoforms. An IgM lambda and an IgA kappa myeloma protein were found in this serum. Immunoblots performed with specific anti-isotype second antibodies showed that the tubulin subset could be evidenced using anti-mu, alpha, lambda, and kappa-specific antisera. Moreover, the tubulin subset was also evidenced using an anti-gamma second antibody. These results, which do not exclude a participation of the myeloma proteins in the anti-tubulin reactivity, indicate, however, that the antibody response was polyclonal. The same restricted specificity of all classes of anti-tubulin antibodies of this serum favours the hypothesis that the immune response of the patient was directed against an antigen sharing epitopes with tubulin rather than with tubulin itself.

摘要

发现一名骨髓瘤患者的血清可修饰培养细胞的微管和有丝分裂纺锤体。一维及二维电泳后进行的免疫印迹显示,该血清与特定的β-微管蛋白亚型发生反应,但与β'-微管蛋白和α-微管蛋白无反应。该微管蛋白亚型包含普遍存在的(β-3)和神经特异性的(β-4、5、6)亚型。在该血清中发现了一种IgM λ型和一种IgA κ型骨髓瘤蛋白。用特异性抗同种型二抗进行的免疫印迹显示,使用抗μ、α、λ和κ特异性抗血清可证实微管蛋白亚型的存在。此外,使用抗γ二抗也证实了微管蛋白亚型的存在。这些结果虽然不排除骨髓瘤蛋白参与抗微管蛋白反应,但表明抗体反应是多克隆的。该血清中所有类别的抗微管蛋白抗体具有相同的受限特异性,这支持了这样一种假说,即患者的免疫反应针对的是与微管蛋白共享表位的抗原,而非微管蛋白本身。

相似文献

1
Human serum reacting specifically with a subset of beta-tubulin isoforms.与人β-微管蛋白亚型的一个子集发生特异性反应的人血清。
Biol Cell. 1988;62(2):157-163.
2
A subpopulation of trypanosome microtubules recognized by a monoclonal antibody to tubulin.被一种针对微管蛋白的单克隆抗体识别的锥虫微管亚群。
EMBO J. 1983;2(4):479-83. doi: 10.1002/j.1460-2075.1983.tb01450.x.
3
Anti-idiotype monoclonal antibodies specific for the MOPC167 anti-phosphocholine transgene-encoded antibody.对MOPC167抗磷酸胆碱转基因编码抗体具有特异性的抗独特型单克隆抗体。
Hybridoma. 1997 Dec;16(6):503-11. doi: 10.1089/hyb.1997.16.503.
4
[Monoclonal IgA serum protein having a poor precipitation reaction to anti-lambda chain antiserum in the patient with multiple myeloma].[在多发性骨髓瘤患者中对抗λ链抗血清沉淀反应较差的单克隆IgA血清蛋白]
Rinsho Byori. 1985 Dec;33(12):1425-9.
5
Novel immunization protocol and ELISA screening methods used to obtain and characterize monoclonal antibodies specific for human light chain variable-region subgroups.用于获取和鉴定针对人轻链可变区亚组的单克隆抗体的新型免疫方案和酶联免疫吸附测定筛选方法。
Hybridoma. 1993 Aug;12(4):475-83. doi: 10.1089/hyb.1993.12.475.
6
Purification and immunoreactivity of monoclonal antibodies against myeloma-lambda chain.抗骨髓瘤λ链单克隆抗体的纯化及免疫反应性
J Tongji Med Univ. 1991;11(4):204-7. doi: 10.1007/BF02888151.
7
Normal human sera contain antibodies directed at Fab of IgA.正常人血清中含有针对IgA Fab段的抗体。
J Immunol. 1987 Apr 1;138(7):2244-8.
8
Monoclonal anti-dipeptide antibodies cross-react with detyrosinated and glutamylated forms of tubulins.单克隆抗二肽抗体与去酪氨酸化和谷氨酰化形式的微管蛋白发生交叉反应。
Cell Motil Cytoskeleton. 1995;30(3):171-82. doi: 10.1002/cm.970300302.
9
[Monoclonal plasmocytic myeloma with 2 paraproteins, IgG kappa and IgG lambdal].伴有两种副蛋白(IgG κ和IgG λ)的单克隆浆细胞骨髓瘤
Nouv Presse Med. 1974 Dec 28;3(45):2707-11.
10
Subclass distribution of human myeloma proteins as determined with monoclonal antibodies.用人单克隆抗体测定人骨髓瘤蛋白的亚类分布。
Immunol Lett. 1987 Oct;16(1):55-7. doi: 10.1016/0165-2478(87)90061-7.